Medicare Enrolled
Dr. Darren Sigal, MD
Medical Oncology · La Jolla, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sigal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sigal?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sigal
Dr. Darren Sigal is a medical oncology specialist in La Jolla, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Sigal performed 191,647 Medicare services across 2,293 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sigal received a total of $278,309 from 69 pharmaceutical and/or device companies across 503 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sigal is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 2% volume in CA
$278,309 industry payments
Medicare Practice Summary
Medicare Utilization ↗191,647
Medicare services
Top 2% in CA for medical oncology
2,293
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~10,647 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Paclitaxel protein-bound particle injection An injection of paclitaxel formulated as protein-bound particles. This code specifies the administration of the medication measured in milligrams. |
56,200 | $10 | $51 |
| Lanreotide injection, 1 mg A 1 mg injection of lanreotide medication administered into the body. |
28,440 | $44 | $315 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
24,488 | $0 | $1 |
| Anti-nausea injection (aprepitant) | 21,710 | $1 | $7 |
| Nivolumab injection (Opdivo) | 12,006 | $20 | $83 |
| Pembrolizumab injection (Keytruda) | 9,600 | $39 | $158 |
| Azacitidine chemotherapy injection An injection of the medication azacitidine, measured at 1 mg per unit. |
7,110 | $0 | $3 |
| Injection, granisetron hydrochloride, 100 mcg | 5,740 | $0 | $3 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
5,074 | $0 | $1 |
| Paclitaxel chemotherapy injection | 4,947 | $0 | $1 |
| Injection, leucovorin calcium, per 50 mg | 2,708 | $3 | $9 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 2,618 | $3 | $12 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
1,803 | $2 | $8 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
1,460 | $14 | $55 |
| Injection, irinotecan, 20 mg | 1,000 | $2 | $19 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
883 | $103 | $350 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
735 | $119 | $479 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
612 | $81 | $1,806 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
412 | $58 | $232 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
384 | $12 | $46 |
| Injection, potassium chloride, per 2 meq | 360 | $0 | $2 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
332 | $146 | $491 |
| Cisplatin chemotherapy injection, 10 mg Administration of a 10 mg dose of cisplatin, a chemotherapy medication, via injection. |
279 | $2 | $6 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
213 | $22 | $94 |
| Injection, granisetron, extended-release, 0.1 mg | 210 | $1 | $1 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
199 | $146 | $468 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
185 | $26 | $104 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
174 | $2 | $15 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
170 | $1 | $1 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
168 | $6 | $39 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
155 | $18 | $70 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
144 | $58 | $236 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
139 | $25 | $100 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
110 | $50 | $200 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
90 | $24 | $110 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
68 | $1 | $10 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
66 | $2 | $10 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
64 | $134 | $453 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
63 | $1 | $6 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
58 | $468 | $4,500 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
54 | $11 | $44 |
| Injection, lorazepam, 2 mg | 49 | $1 | $38 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
47 | $18 | $72 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
43 | $75 | $248 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
40 | $30 | $118 |
| Intravenous chemotherapy injection Chemotherapy medication is administered directly into a vein using a push technique. This method involves injecting the drug through a needle or catheter already placed in the vein. |
40 | $92 | $368 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
40 | $0 | $41 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
35 | $8 | $14 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
31 | $98 | $269 |
| Blood or blood product transfusion The administration of whole blood or specific blood components into a patient's bloodstream. |
29 | $35 | $157 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
22 | $16 | $65 |
| New patient office visit, complex (60-74 min) | 20 | $177 | $598 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
20 | $65 | $187 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.0% high complexity
98.1% medium
1.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$278,309
Total received (2018-2024)
Avg $39,758/year across 7 years
Top 7% in CA for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
69
Companies
503
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$179,992 (64.7%)
Financial / Ownership
Ownership or investment interests, royalties, and licensing fees
$74,500 (26.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$17,451 (6.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,366 (2.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$18,537
2023
$46,037
2022
$44,605
2021
$94,143
2020
$11,452
2019
$48,939
2018
$14,596
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$7,840
E.R. Squibb & Sons, L.L.C.
$3,908
Takeda Pharmaceuticals U.S.A., Inc.
$2,787
Ipsen Biopharmaceuticals, Inc
$1,809
Exelixis Inc.
$1,713
SpringWorks Therapeutics, Inc.
$77
Daiichi Sankyo Inc.
$71
ABBVIE INC.
$56
Eisai Inc.
$50
ARRAY BIOPHARMA INC
$42
Astellas Pharma US Inc
$35
Deciphera Pharmaceuticals Inc.
$29
Aveo Pharmaceuticals, Inc.
$28
Celgene Corporation
$24
Novartis Pharmaceuticals Corporation
$23
Merck Sharp & Dohme LLC
$23
Fennec Pharmaceuticals, Inc.
$22
Top 3 companies account for 78.4% of 2024 payments
All-time payments by company (2018-2024) ›
Celularity Inc.
$75,934
Ipsen Biopharmaceuticals, Inc
$72,760
Celgene Corporation
$35,182
Seagen Inc.
$28,755
Bayer HealthCare Pharmaceuticals Inc.
$21,178
Bayer Healthcare Pharmaceuticals Inc.
$8,914
PFIZER INC.
$8,099
Celularity, Inc.
$5,085
E.R. Squibb & Sons, L.L.C.
$4,386
F. Hoffmann-La Roche AG
$4,065
Takeda Pharmaceuticals U.S.A., Inc.
$2,814
Exelixis Inc.
$1,808
ARRAY BIOPHARMA INC
$1,742
AstraZeneca Pharmaceuticals LP
$1,558
Taiho Oncology, Inc.
$1,386
Amgen Inc.
$667
Merck Sharp & Dohme Corporation
$528
Novartis Pharmaceuticals Corporation
$439
Genentech USA, Inc.
$410
Halozyme Inc
$309
Foundation Medicine, Inc.
$147
Sirtex Medical Inc
$137
Janssen Biotech, Inc.
$131
Boehringer Ingelheim Pharmaceuticals, Inc.
$122
Lilly USA, LLC
$105
ABBVIE INC.
$99
Daiichi Sankyo Inc.
$99
Pharmacyclics LLC, An AbbVie Company
$90
SpringWorks Therapeutics, Inc.
$77
EMD Serono, Inc.
$73
Eisai Inc.
$70
MEDIVATION FIELD SOLUTIONS LLC
$64
Alexion Pharmaceuticals, Inc.
$62
Astellas Pharma US Inc
$59
Lexicon Pharmaceuticals, Inc.
$56
AbbVie Inc.
$55
Teva Pharmaceuticals USA, Inc.
$52
AbbVie, Inc.
$51
Helsinn Therapeutics (U.S.), Inc.
$48
Kyowa Kirin, Inc.
$44
Incyte Corporation
$42
Janssen Pharmaceuticals, Inc
$39
Seattle Genetics, Inc.
$34
Regeneron Healthcare Solutions, Inc.
$33
GENZYME CORPORATION
$32
INSYS Therapeutics Inc
$32
Deciphera Pharmaceuticals Inc.
$29
TESARO, Inc.
$29
Aveo Pharmaceuticals, Inc.
$28
ACCORD HEALTHCARE, INC.
$25
Advanced Accelerator Applications
$24
Merck Sharp & Dohme LLC
$23
Fennec Pharmaceuticals, Inc.
$22
AMAG Pharmaceuticals, Inc.
$21
TerSera Therapeutics LLC
$20
Mylan Pharmaceuticals Inc.
$20
GlaxoSmithKline, LLC.
$20
Pharmacyclics LLC, an AbbVie Company
$19
EISAI INC.
$19
Puma Biotechnology, Inc.
$19
CSL Behring
$16
Aurobindo Pharma USA, Inc.
$16
Spectrum Pharmaceuticals Inc.
$15
Otsuka America Pharmaceutical, Inc.
$14
West Therapeutics Development, LLC
$14
Array BioPharma Inc.
$14
Dova Pharmaceuticals
$11
Amarin Pharma Inc.
$11
Secura Bio, Inc.
$7
Top 3 companies account for 66.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALIMTA · ALOXI · Abraxane · Alecensa · Aliqopa · Aranesp · Avastin · BALVERSA · BENDEKA · BOSULIF · BRAFTOVI · Bavencio · Beleodaq · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CAMCEVI · CREON · CRESEMBA · CYRAMZA · Cabometyx · Cresemba · DARZALEX · Doptelet · ELIQUIS · ELITEK · EMEND · ERBITUX · Enhertu · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Farydak · Folotyn · Fulphila · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · Imbruvica · Inrebic · JADENU · JAKAFI · JEMPERLI · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LUTATHERA · LUTATHERA (lutetium Lu 177 dotatate) · Lazanda · Lenvima · Lonsurf · MEKINIST · MVASI · MYLOTARG · NINLARO · Nerlynx · Neulasta · Nexavar · Non-Covered Product · OGSIVEO · ONIVYDE · OPDIVO · Onivyde · PIQRAY · POTELIGEO · PROMACTA · Pedmark · Perjeta · Polivy · Prolia · QINLOCK · RYDAPT · Revlimid · Rituxan Hycela · SANCUSO · SANDOSTATIN · SANDOSTATIN LAR · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TECENTRIQ · TUKYSA · ULTOMIRIS · Ultomiris · VENCLEXTA · VOTRIENT · Vanflyta · Vascepa · Vectibix · Venclexta · Vitrakvi · XALKORI · XARELTO · XTANDI · Xermelo · Xofigo · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (65%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 7% for medical oncology in CA.
Geographic Context
Medical oncologists within 10 mi
22
Per 100K population
0.7
County median income
$102,285
Nearest hospital
SCRIPPS MEMORIAL HOSPITAL LA JOLLA
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sigal is a mixed practice specialist, with above-average Medicare volume (top 2% in CA), with speaking/promotional industry engagement in the top 7% of CA peers, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sigal experienced with paclitaxel protein-bound particle injection?
Based on Medicare claims data, Dr. Sigal performed 56,200 paclitaxel protein-bound particle injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sigal receive payments from pharmaceutical companies?
Yes. Dr. Sigal received a total of $278,309 from 69 companies across 503 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sigal's costs compare to other medical oncologists in La Jolla?
Dr. Sigal's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sigal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in La Jolla
Browse medical oncologists in La Jolla ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
Celularity Inc. Payments to Doctors
See all physicians who received payments from Celularity Inc.
By company
Ipsen Biopharmaceuticals, Inc Payments to Doctors
See all physicians who received payments from Ipsen Biopharmaceuticals, Inc.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology